KemPharm, Inc., a specialized pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its candidate product includes KP415 and KP484 for the treatment of attention deficit disorder. (ADHD) For reference: ADHD has a huge market and no cures have been invented in over 10 years. If the KP415 is FDA approved (March 2), it will be the first major shift since Vyvanse hit the market in 2007. The ADHD market is priced
at $ 24 billion in 2024. An interesting fact is that Vyvanse was invented by Travis Mikal and his team of scientists while they were working on New River and later acquired this company for 2.6 billion US dollars. This team is currently working on KP415 at KemPharm. With the approval of the drug, the company has great prospects, since this drug is superior to its counterpart, as the developers themselves say. We go in a small position
Short term - 14$
Long term - 20/40$
at $ 24 billion in 2024. An interesting fact is that Vyvanse was invented by Travis Mikal and his team of scientists while they were working on New River and later acquired this company for 2.6 billion US dollars. This team is currently working on KP415 at KemPharm. With the approval of the drug, the company has great prospects, since this drug is superior to its counterpart, as the developers themselves say. We go in a small position
Short term - 14$
Long term - 20/40$